HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis
The Lancet Infectious Diseases | Mar 02, 2018
Gupta RK, et al. - Researchers here aimed at assessing the incidence of HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries. In low-income and middle-income countries (LMICs), pretreatment drug resistance seemed increasing at substantial rate. This was particularly evident in sub-Saharan Africa. In 2016, data from southern and eastern Africa and Latin America showed that the prevalence of pretreatment non-nucleoside reverse transcriptase inhibitors resistance was near WHO's 10% threshold for changing first-line antiretroviral therapy (ART). This highlights the necessity for routine national HIV drug-resistance surveillance and review of national policies for first-line ART regimen composition.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries